Roth Capital Rates Biodesix (BDSX) buy, $32 Price Target

Roth Capital has reaffirmed its buy rating on Biodesix, Inc., setting a price target of $32, a 37.10% upside from the current price.

By EarningsIQ Research Desk · Published Jun 25, 2026, 7:02 AM EDT · Updated Jun 29, 2026, 10:01 AM EDT

Reviewed by automated data checks against the source data. How we make and check alerts

Roth Capital rated Biodesix, Inc. ($BDSX) "buy" with a $32 price target on June 25, 2026.

Since the rating, $BDSX is up 9.7% after 1 week, up 10.9% after 1 month and up 18.1% to date (from the $20.04 close on Jun 25, 2026).

BDSX Biodesix, Inc.

$23.66 +266.25% year to date

Daily close · Oct 16, 2026

Key Points

Roth Capital reiterated its buy rating on Biodesix, Inc. with a price target of $32 as of June 25, 2026.
Roth Capital's $32 price target implies 37.10% upside from Biodesix, Inc.'s ($BDSX) current $23.34 share price.
Biodesix's stock traded near $18.67 on Thursday, with a market cap of approximately $179.7 million.
Several funds, including AIGH Capital Management and Telemark Asset Management, adjusted their positions in Biodesix recently.

Get $BDSX trade alerts by text

We text you when insiders, Congress or big funds trade $BDSX. Free.

Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Biodesix, Inc. alert may contain errors. Disclosures

Roth Capital reiterated its buy rating on Biodesix, Inc. (NasdaqGM: BDSX) on June 25, 2026, maintaining a price target of $32. This suggests confidence in the company's potential growth, as Biodesix shares traded near $18.67 on Thursday.

Analyst rating track record

Roth Capital vs. the S&P 500

YTD return +12.58% hypothetical

All-time return +14.57% S&P 500 +12.92%

vs. S&P 500 +1.65% ahead of the index

Hypothetical returns from Roth Capital's disclosed trades, not real profit or advice. How we model this.

Other Institutional Activity in Biodesix, Inc.

AIGH Capital Management LLC opened a new position in Biodesix with 758,328 shares, valued at about $10.9 million. Telemark Asset Management, LLC increased its holdings by 162,000 shares, ending with 489,824 shares worth approximately $7.1 million, marking a 49.4% increase. Aberdeen Group PLC grew its stake by 196,013 shares to a total of 458,438 shares valued at around $6.6 million, a 74.7% increase. Soleus Capital Management, L.P. also initiated a new position, acquiring 416,599 shares worth about $6 million. Meanwhile, Birchview Capital, LP kept its holdings steady at 286,804 shares, valued at $4.2 million.

Biodesix, Inc. Stock Down 20.1%

Shares of NasdaqGM:BDSX traded near $18.67 on Thursday. Biodesix boasts a market cap of approximately $179.7 million, with a beta of 0.593, indicating lower volatility compared to the market. The stock's 52-week range spans from $5.00 to $20.21, with a 50-day moving average of $14.00 and a 200-day moving average of $10.80. The company has a current ratio of 2.82 and a quick ratio of 2.42, though it has a high debt-to-equity ratio of 805.6.

12-month forecast

$BDSX price target

Biodesix, Inc. daily closes and this analyst's $32 target. Not advice.

Recent Earnings

Biodesix reported revenue of $96.1 million, with a year-over-year growth of 42.3%. However, the company posted a net margin of -33.3% and a return on equity of -316.5%, indicating financial challenges. The next earnings report is expected on August 6, 2026.

Insider Buying and Selling at Biodesix, Inc.

Insider transactions include Patience John, who both sold and bought 1,361 shares on March 31, 2026. On February 23, 2026, multiple executives, including CFO Robin Harper Cowie, Chief Accounting Officer Chris Vazquez, and Chief Commercial Officer Kieran O'Kane, sold 535 shares each at an average price of $12.78. President and CEO Scott Hutton also sold 1,490 shares on the same date.

Analysts Set New Price Targets

On June 25, 2026, Roth Capital reiterated its buy rating for Biodesix, setting a price target of $32. Earlier, on June 18, 2026, Canaccord Genuity maintained a buy rating with a target of $27. HC Wainwright & Co. also initiated coverage with a buy rating and a $26 target on June 15, 2026. The consensus recommendation is a strong buy, with an average target price of $30.60 from five analysts.

About Biodesix, Inc.

Biodesix, Inc. is a healthcare company based in Louisville, Colorado, specializing in diagnostic solutions. It provides blood-based tests for lung cancer risk assessment and treatment guidance through products like Nodify Lung Nodule Risk Assessment and IQLung testing strategy. The company also offers services such as biomarker discovery and clinical trial testing for biopharmaceutical firms. Biodesix employs 334 people and is led by CEO Scott Hutton.

Bottom Line

Roth Capital's reiterated buy rating on Biodesix with a $32 price target highlights ongoing confidence in the company's prospects. The stock's recent trading activity and institutional interest indicate a dynamic market presence. As always, remember that these analyst ratings are backward-looking and may not reflect future performance.